These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 6638984

  • 1. [Urinary excretion of rifampicin in kidney failure when administered alone or together with isoniazid].
    Titarenko OT, Vakhmistrova TI, Perova TL.
    Antibiotiki; 1983 Sep; 28(9):698-702. PubMed ID: 6638984
    [Abstract] [Full Text] [Related]

  • 2. [Biotransformation of rifampicin in pulmonary tuberculosis patients].
    Ioffe RA.
    Antibiotiki; 1977 Sep; 22(2):177-80. PubMed ID: 558736
    [Abstract] [Full Text] [Related]

  • 3. Bioavailability of rifampicin, isoniazid and pyrazinamide in a triple drug formulation: comparison of plasma and urine kinetics.
    Gurumurthy P, Ramachandran G, Vijayalakshmi S, Kumar AK, Venkatesan P, Chandrasekaran V, Vjayasekaran V, Kumaraswami V, Prabhakar R.
    Int J Tuberc Lung Dis; 1999 Feb; 3(2):119-25. PubMed ID: 10091876
    [Abstract] [Full Text] [Related]

  • 4. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 5. The potential use of urinary excretion data for assessing the relative bioavailability of rifampicin in fixed dose combination anti-tuberculosis formulations.
    Pillai G, Ellard GA, Smith PJ, Fourie PB.
    Int J Tuberc Lung Dis; 2001 Aug; 5(8):691-5. PubMed ID: 11495257
    [Abstract] [Full Text] [Related]

  • 6. Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels.
    Agrawal S, Singh I, Kaur KJ, Bhade SR, Kaul CL, Panchagnula R.
    Int J Pharm; 2004 May 19; 276(1-2):41-9. PubMed ID: 15113612
    [Abstract] [Full Text] [Related]

  • 7. [Quantitative determination of isoniazid and rifampicin in the urine of patients treated with combination of drugs].
    Svinchuk VS.
    Probl Tuberk; 1989 May 19; (10):61-2. PubMed ID: 2594718
    [No Abstract] [Full Text] [Related]

  • 8. [Pharmacokinetic interaction of ketoconazole, isoniazid and rifampicin].
    Pilheu JA, Galati MR, Yunis AS, De Salvo MC, Negroni R, García Fernández JC, Mingolla L, Rubio MC, Masana M, Acevedo C.
    Medicina (B Aires); 1989 May 19; 49(1):43-7. PubMed ID: 2698437
    [Abstract] [Full Text] [Related]

  • 9. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program .
    Natl Toxicol Program Tech Rep Ser; 1996 Aug 19; 383():1-370. PubMed ID: 12692653
    [Abstract] [Full Text] [Related]

  • 10. Single dose kinetics of rifampicin and isoniazid in well-nourished and malnourished patients of tuberculosis.
    Garg SK, Dhand R, Malik SK, Kalra S, Gupta PH, Jha VK, Shukla VK, Lal R.
    Int J Clin Pharmacol Ther Toxicol; 1988 Aug 19; 26(8):417-20. PubMed ID: 3220617
    [Abstract] [Full Text] [Related]

  • 11. Bioequivalence study of rifampicin in fixed-dose combination of rifampicin and isoniazid vs. separate formulations.
    Panchagnula R, Singh I, Kaur KJ, Kaul CL.
    Methods Find Exp Clin Pharmacol; 1999 Nov 19; 21(9):625-8. PubMed ID: 10669909
    [Abstract] [Full Text] [Related]

  • 12. Kinetics of rifampicin and isoniazid administered alone and in combination to normal subjects and patients with liver disease.
    Acocella G, Bonollo L, Garimoldi M, Mainardi M, Tenconi LT, Nicolis FB.
    Gut; 1972 Jan 19; 13(1):47-53. PubMed ID: 5060669
    [Abstract] [Full Text] [Related]

  • 13. [Acute toxic action of combinations of antibiotics with isoniazid].
    Ziia AV, Sokolova GB, Lebedeva MN.
    Antibiotiki; 1982 Jan 19; 27(7):535-9. PubMed ID: 7137978
    [Abstract] [Full Text] [Related]

  • 14. [Antibacterian activity modifications of serum isoniazid when using it with rifampicin (author's transl)].
    Nouhouayi A, Bergogne-Berezin E, Lafaix C.
    Pathol Biol (Paris); 1982 Jun 19; 30(6):389-93. PubMed ID: 7050848
    [Abstract] [Full Text] [Related]

  • 15. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W, Nagayama N, Miyamoto M, Hara H, Suzuki J, Masuda K, Baba M, Tamura A, Nagai H, Akagawa S, Kawabe Y, Machida K, Kurashima A, Yotsumoto H.
    Kekkaku; 2003 Oct 19; 78(10):611-7. PubMed ID: 14621568
    [Abstract] [Full Text] [Related]

  • 16. Bioavailability of rifampicin, isoniazid and pyrazinamide from fixed-dose combination capsules.
    Zwolska Z, Niemirowska-Mikulska H, Augustynowicz-Kopec E, Walkiewicz R, Stambrowska H, Safianowska A, Grubek-Jaworska H.
    Int J Tuberc Lung Dis; 1998 Oct 19; 2(10):824-30. PubMed ID: 9783530
    [Abstract] [Full Text] [Related]

  • 17. Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis.
    Nijland HM, Ruslami R, Suroto AJ, Burger DM, Alisjahbana B, van Crevel R, Aarnoutse RE.
    Clin Infect Dis; 2007 Oct 15; 45(8):1001-7. PubMed ID: 17879915
    [Abstract] [Full Text] [Related]

  • 18. Circadian variations in urine excretion in chronic renal failure.
    Hillier P, Knapp MS, Cove-Smith R.
    Q J Med; 1980 Oct 15; 49(196):461-78. PubMed ID: 7267962
    [Abstract] [Full Text] [Related]

  • 19. The effect of antipyrine and rifampicin on the excretion of renal enzymes in human urine.
    Wensing G, Maruhn D, Ohnhaus EE.
    Clin Nephrol; 1988 Feb 15; 29(2):69-74. PubMed ID: 2896083
    [Abstract] [Full Text] [Related]

  • 20. [The validation of the adequacy of chemotherapy in bladder tuberculosis based on a study of bacteriostatic activity].
    Dovlatian AA, Dzhenzhera NA.
    Probl Tuberk; 1992 Feb 15; (11-12):49-51. PubMed ID: 1289890
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.